RxDoctor Payments Data

Shahina Motorwala, MD

Adolescent Medicine · Westland, MINPI 1841312659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Lilly USA, LLC at 24.9% of the total.

$382in general payments, 2019–2025

Across 22 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$95
  • GSK$85
  • Pfizer$83
  • AstraZeneca$62
  • AbbVie$28
  • Phadia US Inc.$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$382 in reported general payments places this provider in the 60th percentile of 70 adolescent medicine providers in Michigan.

See all adolescent medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$33,664
Medicare patients
52
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$71,661
TrulicityDulaglutide27$38,456
OzempicSemaglutide18$25,447
MounjaroTirzepatide20$24,301
JanuviaSitagliptin Phosphate16$16,735
EliquisApixaban21$15,364
FarxigaDapagliflozin Propanediol11$11,217
Breo ElliptaFluticasone/Vilanterol13$8,411
Pregabalin36$3,074
Albuterol Sulfate HfaAlbuterol Sulfate66$2,999
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$1,609
Amlodipine-AtorvastatinAmlodipine/Atorvastatin11$1,387
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic17$1,334
Atorvastatin Calcium166$1,316
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$85$80,07297 claims
Lilly USA, LLCTrulicity, Mounjaro$95$62,75747 claims
PfizerEliquis$83$15,36421 claims
AstraZenecaFarxiga$62$11,21711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 70 adolescent medicine providers in Michigan.

Other adolescent medicine in Westland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →